Donna-- if you want to question neuro about Requip progression, you might tell
him that some folks have been started out on a more gradual dose, to avoid
hallucinations,etc.  In Peter's case, because that was the problem with the
Mirapex/Sinemet combo, we were started on ONE ).25 tab 3 X a day, and it
took 9 weeks instead of 3 to reach the end of the sample kit....but no bad
side effects either, and Sinemet was concurrently reduced. He is only now
taking 3/3/4, and I hope can take more soon--but sometimes patience pays
off! Good luck to your dad.




>Well my dad has his N appt yesterday - and as we figured he's switching him to
>Requip.
>N says - R is more flexible in dosage than Mirapex - so we should be able
>to find
>a dose thats right for him. I don't know why he refuses to accept than less
>than 3mg/day of Mirapex is OK - many of you do that. I should probably
>contact the pharm rep and get him more literature.
>
>ANyway - we're going doin on the M ... he was at 0.25mg - 6 pills a day -
>we're going to 4 this week and then 2 then a week without anything ...
>what can we expect ? will this be a nightmare ?
>
>Then the next week we start on Requip - following the sample kit (we didn't
>get no free offers either !!).
>
>Has anyone else been here - done this ? Any advice is welcomed.
>
>Have a nice day
>
>donna
>
>
>
>
>------------------------------------------------------------------------------
>-                  Donna Bassolino-Klimas,  Ph.D.
>                   Bristol Myers Squibb Pharma. Res. Inst.
>                   Department of Macromolecular Structure
>                   P.O. Box 4000    Room H3812
>                   Princeton, N.J.  08543 4000
>
>                   (609) 252 4413
>                   INTERNET:  [log in to unmask]
>
>------------------------------------------------------------------------------


  Camilla Flintermann, CG for Peter 79/8
  Oxford, OH
  [log in to unmask]
 * * * * * * * * * * * * * * * * *
 * Ask me about the CARE list for*
 *   Parkinson's caregivers !    *
 * * * * * * * * * * * * * * * * *